Work

Supplementary Table S4 from Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer

Year: 2026

Type: supplementary-materials

Abstract: Supplementary Table 4. The results of the statistical analysis used to assess additive vs synergistic effect of ibrutinib in combination with CAR-T cells is shown for Fig 5B.

DOI: 10.1158/1078-0432.31248833

Authors: Alexander Armstrong, Graziella van der Plancke, Sae Nishiguchi, Diego Salas-Benito, Amanda A. Bouffard, Sadie Goncalves, Ashlyn T. Merce, Christopher Kelly, Filippo Birocchi, Sangwoo Park, Mark B. Leick, Nora Horick, Trisha R. Berger, Marcela V. Maus, Giulia Escobar

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W7127709151

Cites:

Cited by:

Related to: 10